Mobile

A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate vaccine containing the adjuvant AS25 (FluAS25) in...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001928-37

A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate vaccine containing the adjuvant AS25 (FluAS25) in an elderly population aged over 65 years (>65 years-old) previously vaccinated in 2004 with the same candidate vaccine in FLUAS25-001 clinical trial. For immunogenicity and safety evaluations, Fluarix™ (known as alpha-Rix™ in Belgium)vaccine will be used as reference

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and reactogenicity of a revaccination with adjuvanted vaccine FluAS25 during 21 days following the intramuscular administration of the vaccine. Fluarix will be used as reference.

Critère d'inclusion

  • Immunisation against influenza disease in elderly population aged over 65 years (>65 years)

Liens